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Purpose: To investigate the contribution of cytochrome P4501B1 (CYP1B1) and myocillin (MYOC) mutations to primary
congenital glaucoma (PCG) in Moroccan families.
Methods: This study included 90 unrelated families with PCG and 100 normal control individuals. Two previously
reported CYP1B1 mutations (g.4339delG and p.G61E) were first screened by polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP). The coding exons of CYP1B1 were sequenced in g.4339delG- and p.G61E-
negative or heterozygous probands. Then the coding exons of MYOC were sequenced in patients who had no mutation in
CYP1B1 or carried heterozygous CYP1B1 mutation.
Results: Twelve CYP1B1 mutations were identified in 43 PCG pedigrees. Three of them were novel (p.R163C, p.C470Y,
and g.4330–4331delTG) and associated with moderate to severe phenotypes. Two novel intronic polymorphisms in
CYP1B1 were identified in addition to those previously described. The g.4339delG was the most frequent mutation
detected in 31 families (34.44%), followed by the p.G61E in seven families (7.77%). The remaining mutations (p.R163C,
p.E173K,  g.4330–4331delTG,  p.E229K,  p.R390S,  p.R368H,  p.R469W,  p.C470Y,  and  g.7901–7913del13bp)  were
infrequent. One family with the p.R390S mutation showed both PCG and primary open angle glaucoma (POAG)
phenotypes. One proband was heterozygous for p.T193K mutation in MYOC. This mutation has been initially associated
with POAG, but never with PCG.
Conclusions: Our results support that mutations in CYP1B1 are a major cause for PCG in the Moroccan population with
a predominance of the g.4339delG mutation. Furthermore, these results demonstrate the diversity of CYP1B1 mutations,
while suggesting a modest role of MYOC in Moroccan PCG.
Primary congenital glaucoma (PCG, OMIM 231300) is
characterized by a marked increase of intraocular pressure at
birth or early childhood, large ocular globes (buphthalmos),
corneal edema, and Haab’s striae [1-3]. It is associated with
developmental defects in the anterior chamber and is mainly
inherited as an autosomal recessive disorder with incomplete
penetrance  [4,5].  The  incidence  of  PCG  varies  among
geographic locations and ethnic communities, from 1:10,000–
20,000 in western countries, to 1:2,500 and 1:250 in inbred
Slovakian Gypsy and Saudi Arabian populations, respectively
[3].  So  far,  three  genetic  loci  have  been  linked  to  PCG:
GLC3A (chromosome 2p21), GLC3B (chromosome 1p36),
and GLC3C (chromosome 14q24.3). The only gene that has
been identified is the cytochrome P4501B1 gene (CYP1B1)
linked to GLC3A [4,6].
Mutations in CYP1B1 are the major cause of PCG with
more than a hundred that have been reported in the Human
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Gene Mutation Database [2]. Nonetheless, limited role of
myocillin (MYOC at chromosome 1q24–25) [7-9], forkhead
box  C1  (FOXC1  at  chromosome  6p25)  [10],  and  latent
transforming growth factor beta binding protein 2 (LTBP2;
close to the GLC3C locus) [11,12], has been suggested in PCG
pathogenesis. In some studies, CYP1B1 mutations have been
reported to be associated with primary open-angle glaucoma
(POAG, OMIM 137760) [13-17]. However, their contribution
to  the  occurrence  of  POAG  was  controversial.  Recently,
extended studies and functional analysis demonstrated that
heterozygous  CYP1B1  mutations  with  absent  or  reduced
function can be considered as a risk factor for POAG [18,19].
CYP1B1 mutations are also detected in Rieger’s anomaly [2,
20,21], Peters’ anomaly, and Sturge-Weber syndrome [22]. In
certain pedigrees, both PCG and POAG segregate [23-25].
Some patients with PCG exhibit mutations in both CYP1B1
and MYOC [7,26]. The human CYP1B1 gene consists of three
exons, two of which are coding. The CYP1B1 protein is a
member of the cytochrome P450 superfamily (subfamily I)
[27]. The only reported mutational analysis of CYP1B1 in
PCG patients from Morocco has been performed on isolated
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1215cases  and  identified  only  two  mutations:  g.4339delG  and
p.G61E [28].
To further evaluate the role of CYP1B1 mutations in
Moroccan PCG, as well as the presumptive contribution of
MYOC in the disease, we investigated the mutation spectrum
of these two genes in a large cohort of unrelated Moroccan
PCG families.
METHODS
Patients: This research adhered to the tenets of the Declaration
of Helsinki. The patients were referred for evaluation of their
glaucoma  to  the  Department  of  Ophthalmology  of  the
University Ibn Sina Hospital in Rabat, Morocco. A total of
187 individuals were included in this study. They belonged to
90 unrelated Moroccan PCG families residing in different
regions of Morocco and comprising 90 probands, 18 affected
and 79 non-affected relatives. Control DNAs (n=100) were
obtained from randomly selected healthy adults. All subjects
gave their informed consent. All patients were examined by
at least one ophthalmologist.
Ophthalmological  examinations  included
biomicroscopy, gonioscopy, and measurement of intraocular
pressure  (IOP)  by  Perkins  tonometers,  and  optic  nerve
examination. IOP and corneal diameter were measured under
general anesthesia. Inclusion criteria were: increased corneal
diameter (>12.0 mm), raised IOP (>21 mHg) with or without
Haab’s  striae,  and  optic  disc  changes  whenever  anterior
segment  conditions  made  fundus  examination  possible.
Additional inclusion factors were epiphora and photophobia.
Trabeculectomy  was  the  initial  surgical  procedure.
Trabeculectomy with Mitomycin C was performed on second
attempt. Individuals presenting with other ocular or systemic
anomalies were excluded. Clinical features of 20 of the 90
probands with mutations are shown in Table 1.
CYP1B1 and MYOC mutation screening: Patient's genomic
DNA was extracted from peripheral blood leucocytes using
standard phenol/chlorophorm procedure. Polymerase chain
reaction–restriction  fragment  length  polymorphism  (PCR-
RFLP) was performed for rapid detection of g.4339delG and
p.G61E mutations. The coding exons of CYP1B1 were then
analyzed by direct sequencing in g.4339delG- and p.G61E-
negative or heterozygous cases. Then the coding exons of
MYOC were sequenced in patients who had no mutation in
CYP1B1 or carried heterozygous CYP1B1 mutation. When a
mutation was found, parents and all available related family
members were tested.
The g.4339delG mutation abolishes a Hae II restriction
site and the p.G61E creates a TaqI site. Genomic DNA of all
patients was first amplified by PCR using primers surrounding
the two mutations. The PCR-products were then digested by
Hae II and TaqI according to the conditions specified by the
manufacturers (Promega, Madison, WI), and separated on 2%
agarose gel electrophoresis. Exons 2 and 3 of CYP1B1 as well
as exons 1, 2, and 3 of MYOC and their flanking intronic
regions were amplified by PCR using intronic primers close
to the intron/exon boundary. They were then sequenced using
intronic and internal primers. PCR products were purified
using  the  “PCR  Clean-Up  System  Kit”  (Promega)  and
sequenced  on  an  ABI  PRISM  3100  automated  sequencer
(Applied  Biosystems,  Foster  City,  CA).  All  the  primers’
sequences used in this study are shown in Table 2.
Computational  analysis:  Two  homology-based  programs
PolyPhen  (Polymorphism  Phenotyping)  [29,30]  and  SIFT
(sorting  intolerant  from  tolerant  homology)  were  used  to
assess  the  functional  effect  of  the  substituted  amino-acid
[31,32].  Polyphen  PSIC  (position  specific  independent
counts) scores of >2.0 indicate that the variation is probably
damaging to protein function. Scores of 1.5–2.0 are possibly
damaging,  and  scores  <1.5  are  likely  benign.  The  SIFT
threshold  score  of  less  than  0.05  was  considered  to  be
deleterious to the protein. We also used PolyPhen-2 program
(PolyPhen v.2) whose performance is consistently superior to
that of PolyPen [33]. Multiple alignments of CYP1B1 from
different species were preformed using clustalW software.
Mutation nomenclature: Mutations and polymorphisms were
named based on the genomic DNA sequences U56438 and
NT_004487 of CYP1B1 and MYOC, respectively.
RESULTS
Clinical  features  of  patients:  To  investigate  the  role  of
CYP1B1  mutations  in  Moroccan  patients  with  PCG,  we
studied a total of 90 unrelated families affected by the disease.
The  presumed  mode  of  inheritance  of  PCG  according  to
pedigree  analysis  was  autosomal  recessive  in  all  families
except one who showed a pseudo-dominance mode (data not
shown). Consanguinity was found in 47 of the 90 families
(52%). More than one individual were affected in 27 families
(30%). Among the 90 probands, 52 (58%) were male and 38
(42%) were female. The age of the onset of disease ranged
from one day to 6 months (median 26 days).
At the time of the first specialized consultation (time of
diagnosis),  their  ages  ranged  from  15  days  to  19  months
(median 7 months). The disease was bilateral in 82 patients
(91.11%). Severe opacities were present in 75 eyes (41.66%),
edema in 118 eyes (65.55%) and Haabs striaes in 38 eyes
(21.11%).  Corneal  diameters,  measured  under  general
anesthesia, ranged from 11 to 18 mm with an average of
14.05±1.8  mm.  The  mean  measured  IOP  before  the  first
surgical procedure was 30.6±7.5 mmHg. The average cup-to-
disk size ratio was 0.67±0.2. Trabeculectomy was performed
as  the  initial  surgical  procedure  in  126  eyes  (70%),  and
surgical data were not available for 38 eyes (21.11%). Forty
eyes (22%) needed more than one surgery. Two eyes were
blind at the time of diagnosis. Ten others became blind during
the follow-up, and finally one eye had to be enucleated due to
the consequences of uncontrollable IOP.
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1217CYP1B1 mutational analysis: A total of 11 distinct CYP1B1
mutations  was  identified  in  43  (47.77%)  of  90  unrelated
probands:  8  substitutions  (g.3987G/A,  g.4292C/T,  g.
4322G>A, g.7927G/A, g.7940G>A, g.8005C>A, g.8242C/T,
and  g.8246C/A)  predicting  missense  mutations  (p.G61E,
p.R163C, p.E173K, p.V364M, p.R368H, p.R390S, p.R469W,
and p.C470Y) and 3 nucleotide deletions (g.4339delG, g.
4430–4431delTG,  and  g.7901–
7913delGAGTGCAGGCAGA  [g.7901–7913del13bp])
resulting  in  three  frameshift  mutations  followed  by  stop
codons at position 179, 222, and 422, respectively (Table 1,
Figure 1). For the second deletion, because of a three GT
repeat at nucleotide position 4427–4432, it is not possible to
determine  exactly  which  of  the  positions  is  deleted.  This
deletion was arbitrarily named g.4430–4431delTG.
Eight of these mutations have been previously described
as  disease-causing  in  different  populations  (p.G61E,
p.E173K,  p.V364M,  p.R368H,  p.R390S,  p.R469W,  g.
4339delG,  and  g.7901–7913del13bp)  [2,34,35].  An
additional  previously  reported  mutation  p.E229K  was
detected in the mother of patient PCG-64-III-1 (Figure 1). To
the best of our knowledge, the remaining mutations p.R163C
(rs104894978),  p.C470Y  (rs104894979),  and  g.4330–
4331delTG (rs104894980) were novel (Figure 2).
The detected mutations were present in the probands as
follow: 34 (37.77%) were homozygous (24 for g.4399delG,
five for p.G61E, one for p.R390S, one for p.C470Y, one for
p.R469W, one for g.4430–4431delTG, and one for g.7901–
7913del13bp).  Seven  mutations  (7.77%)  were  compound
heterozygous  (two  g.4339delG/  p.G61E,  two  g.4339delG/
p.E173K,  one  g.4339delG/p.V364M,  one  g.4339delG/g.
4430–4431delTG,  and  one  g.4339delG/g.7901–
7913del13bp). Two (2.22%) were heterozygous carrying only
one mutated allele (p.R163C and p.R368H).
No other mutations were detected in the probands. Only
14  polymorphic  variants  were  identified:  g.3748G>A,  g.
3791C>T,  g.3793T>C,  g.3947C>G  (p.R48G),  g.3952C>A
(p.S49S), g.4160G/T (p.A119G), g.4369C/A (p.G188G), g.
4534G/C (p.V243V), g.7870C/A, g.7915T/C (p.L360L), g.
8131C>G  (p.L432V),  g.8165C>G  (p.A443G),  g.8184T/C
(p.D449D),  and  g.8195A>G  (p.N453S).  Two  of  them:  g.
3748G>A (ss244236418) and g.7870C/A (ss244236419) are
reported herein for the first time. These intronic variations
were  found  in  both  PCG  chromosomes  and  control
TABLE 2. PRIMER SEQUENCES USED IN THIS STUDY.
Gene Primer Exon Sequence (5’-3’)
Annealing
temperature °C
Product size
(bp)
CYP1B1 C2F1,2 2 ACCCAACGGCACTCAGTC 58 1232
  C2R1   CCCTGCTTGCAAACTCAGC    
  C2.1F2,3   GCTCCTGTCTCTGCACC 58 636
  C2.1R2,3   GCCTCGGGTCGAGGAAG    
  C2.2F2   CTTCTTCACGCGCCAGC   651
  C2.2R2   CATATTCTGTCTCTACTCCGCC    
  C2.3F2,4   ATGGCTTTCGGCCACT 60 264
  C2.3R2,4   GGGGTCGTCGTGGCTGTAG    
  C3F1,2 3 AATGGGAAAGACAGCATTAGTC 60 1007
  C3R1,2   ATGAAGAACCGCTGGGTATG    
  C3.1F2   AGTGAGAAATTAGGAAGCTGTTTT   595
  C3.1R2   AGCCAGGATGGAGATGAAGA    
MYOC M1F1 1 GCCACCTCTGTCTTCCCC 60 853
  M1R1   CTCTAGGAGAAAGGGCAGGC    
  M1.1F2   CAGGCACCTCTCAGCACAG    
  M1.1R2   AGCCCCTCCTGGGTCTC   406
  M1.2F2   ACCCAACGCTTAGACCTGG   432
  M1.2R2   TGTAGCAGGTCACTACGAGCC    
  M2F1 2 CCACATCCAGCTAATTCTTTTG 58 553
  M2R1   AGACCTGCTCTGACAAGGGA    
  M3F1 3 CAGACGATTTGTCTCCAGGG 55 1020
  M3R1   GAAAGCAGTCAAAGCTGCCT    
  M3.1F2   CATGATCATTGTCTGTGTTTG   521
  M3.1R2   GCTGTAAATGACCCAGAGGC    
  M3.2F2   GAGAAGGAAATCCCTGGAGC   500
  M3.2R2   CCAGGAGCCCTGAGCATC    
In the “primer” column, F indicates forward primer and R indicated reverse primer.  1Primers used for amplification of CY1B1
and  MYOC  genes,  2primers used for DNA sequencing,  3,4primers used for p.G61E and g.4339delG screening, by PCR-RFLP,
respectively. bp: base pair.
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1218chromosomes.  The  frequency  of  g.3748G>A  was  0.93%
(1/108) in the sequenced PCG chromosomes and 1% (2/200)
in control chromosomes. While, the frequency of g.7870C/A
variation was 1.85% (2/108) in the sequenced chromosomes
and 1.5% (3/200) in control chromosomes. This suggests that
these substitutions are polymorphisms rather than causative-
disease mutations.
Novel CYP1B1 mutations: The g.4330–4331delTG resulted
in a frameshift after residue 208 leading to a premature stop
codon  in  the  helix-F,  13  amino-acids  downstream  from
Val208  (p.C209fsX222).  The  g.4330–4331delTG  was
detected in two patients, one of them from a consanguineous
family with two affected subjects and the other one was an
isolated case of PCG. The first patient PCG-84-V.2 and his
affected brother (PCG-84-V.3) were homozygous for g.4330–
4331delTG and both parents were heterozygous for the same
mutation.  The  patient  PCG-64-III.1  was  compound
heterozygous for g.4339delG and g.4430–4431delTG. The
father (PCG-64-II.3) and the paternal grandmother (PCG-64-
I.2) were heterozygous for g.4339delG. The healthy mother
(PCG-64-II.4)  was  heterozygous  carrier  of  g.4330–
4331delTG.  Intriguingly,  her  second  allele  carried  the
p.E229K mutation.
The  other  novel  missense  mutations  p.R163C  and
p.C470Y lie in the loop connecting C- and D-helices, and HBL
(heme binding loop) region of CYP1B1, respectively. The
p.R163C mutation was identified in a non consanguineous
family (Figure 1 and Figure 2). The proband (PCG-101-III.3),
the  father  (PCG-101-II.1)  and  the  paternal  grandmother
(PCG-101-I.2) were heterozygous for the same mutation. One
of the unaffected sisters (PCG-101-III.2) and the paternal
grandfather  (PCG-101-I.1)  didn’t  carry  the  mutation.  The
Figure  1.  Pedigrees  of  PCG  families
with CYP1B1 or MYOC mutations. A:
Families  with  the  CYP1B1  novel
mutation  (p.R163C,  p.C470Y,  and  g.
4330–4331delTG)  identified  in  this
study.  B:  Family  PCG-40  with  the
CYP1B1  p.R390S  mutation  showing
variable  expression  of  the  PCG
phenotype. The proband (PCG-40-IV.6)
was affected with PCG, while his uncle
(PCG-40-III.1; gray symbol) developed
POAG  at  the  age  of  45.  C:  Family
PCG-9 with MYOC mutation. Deceased
individuals  are  denoted  by  diagonal
slashes, and consanguineous marriages
by  double  lines.  Asterisks  indicate
probands.  Genotypes  in  available
subjects  are  indicated  below  the
symbols. delG: g.4339delG, delTG: g.
4430–4431delTG, w: normal allele.
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1219mother  (PCG-101-II.2)  was  heterozygous  for  p.G61E.
Surprisingly,  the  patient  (PCG-101-III.3)  didn’t  carry  this
mutation, while his sister (PCG-101-III.1) was heterozygous.
No mutation was found in the coding region of MYOC in the
proband  (PCG-101-III.3)  except  previously  reported
polymorphisms.
The p.C470Y mutation was homozygous in the proband
PCG-100-II.3 belonging to a consanguineous and multiplex
family. Unfortunately, the DNAs of the other family members
were not available for further screening. None of the novel
mutations was found in 100 unrelated control subjects.
CYP1B1  haplotype  analysis:  Single  nucleotide
polymorphisms (SNPs) (g.3947C/G, g.4160G/T, g.8131/G,
and g.8195A/G) were analyzed in PCG patients and normal
controls. As the first step of our screening strategy was based
on the screening of g.4339delG and p.G61E by PCR-RFLP,
only  few  probands  (eight)  carrying  these  mutations  were
sequenced and their haplotype constructed and only patients
in  whom  a  complete  haplotype  could  be  determined  was
included. Therefore, the haplotypes of a total of 20 PCG
probands with CYP1B1 mutations, 46 PCG probands without
CYP1B1 mutations, and 100 normal controls were analyzed.
C/G/G/A  haplotype  was  the  most  common  haplotype
(75%,  15/20)  among  the  patients  who  carried  CYP1B1
mutations  (Table  3).  Moreover,  the  C/G/G/A  haplotype
background was associated with seven of the 11 identified
mutations  (p.G61E,  p.E173K,  g.4339delG,  g.7901–
7913del13bp, p.V364M, and p.R469W). However, among the
patients  without  mutations  and  normal  controls,  the  most
frequent haplotype was C/G/CG/A (41.3%, 19/46 and 40%,
40/100; respectively) (data not shown).
MYOC  sequence  analysis:  Sequence  analysis  of  MYOC
revealed a heterozygous substitution (g.16 072C/A) in only
one patient (PCG9-II.3, Figure 1), resulting in a missense
mutation  (p.T293K).  This  mutation  has  been  previously
reported  in  patients  with  POAG  and  ocular  hypertension
[26,36-38]. The p.T293K was not found in 98 control subjects.
This is the first time that this mutation is reported in patient
with PCG. No other disease-causing mutations were found.
Only single nucleotide polymorphisms previously described
were  identified  in  exon  1  (g.349G/A,  p.R76K;  g.388C/T,
p.G122G; g.445C/T, p.A141A) and exon 3 (g.16169 G/A,
p.T325T; g.16235C/A, p.Y347Y).
DISCUSSION
This is the first report of the CYP1B1 mutation spectrum in a
large sample of Moroccan families. It is also the first time that
screening of MYOC has been reported in Morocco. CYP1B1
is  considered  as  a  major  cause  for  PCG  in  different
populations and mutations have been reported with variable
frequency depending on ethnic and geographical differences
[2,3].
CYP1B1  mutation  frequency  in  primary  congenital
glaucoma  in  Morocco:  In  this  study,  47.77%  (43/90)  of
probands with PCG had CYP1B1 mutations. This percentage
is similar to the one reported in French (48%) [23], Brazilian
(50%) [39], and Indian (40%) [40] populations. However, it
is lower than the 70 to 100% percentage previously reported
in the more homogeneous and inbred populations of Slovakia
Roma [41], Saudi Arabia [5], Kuwait [42], and Iran [35]. Our
mutation rate is also higher than the percentages reported in
ethnically  mixed  populations  such  as  Indonesian  (22.2%)
[43], Japanese (20%) [44], Australian (21.62%) [24], and
Figure  2.  Detection  of  three  novel
CYP1B1 mutations in Moroccan PCG
families  by  direct  DNA  sequencing.
Sequencing  results  of  probands  from
families PCG-101 (A), PCG-100, and
PCG-64  (B)  and  PCG-84  (C).
Chromatogram  of  a  heterozygous
subject for g.4330–4331delG is shown
in C. The names of the mutations and
their corresponding amino-acid change
are indicated above each chromatogram.
Control  sequences  are  shown  for
comparison purposes. Arrows indicate
the  changed  nucleotides  and  curley
bracket the deleted nucleotides in the g.
4330–4331delTG allele. Because of the
presence of a three GT repeat in this
region, it is not possible to determine
exactly which of the positions is deleted.
Therefore, the position of this deletion
was  arbitrarily  indicated.  Htr:
heterozygous  mutation  and  Hmz:
homozygous mutation.
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1220Chinese  (17.2%)  [9].  It  is  also  slightly  higher  than  the
corresponding figures of Spanish (34%) [25] and Moroccan
PCG (34%) [28] populations. This difference is probably due
to the patients’ geographical locations, as well as the sample
composition  (familial/sporadic,  consanguinity  rate,
unilateral/bilateral)  and  size.  Among  the  43  mutated
probands, consanguinity was found in 29 cases (67.44%), and
19  (44.18%)  of  them  had  a  positive  family  history.
Homozygosity of the mutant alleles was found in 79.06%
(34/43), and compound heterozygosity in 16.27% (7/43) of
the cases. Among the mutated patients two (4.65%) were
heterozygous  for  only  one  mutation  in  CYP1B1.  In  each
family,  when  relatives  are  available,  the  mutant  alleles
segregated  with  the  disease  phenotype  in  an  autosomal
recessive pattern, except in pedigree PCG-64 in which the
healthy mother carried two potentially mutated alleles (Figure
1). This case is discussed below.
CYP1B1 mutations in primary congenital glaucoma in
Morocco: Among the 12 detected mutations, seven missense
mutations (p.G61E, p.E173K, p.E229K, p.R368H, p.V364M,
p.R390S, and p.R469W), and two deletions (g.4339delG and
g.7901–7913del13bp) were previously reported in patients
from different populations [2]. To the best of our knowledge,
three of them were novel (p.R163C, p.C470Y, and g.4330–
4331delTG)  and  five  (p.R368H,  p.V364M,  p.R390S,
p.R469W, and g.7901–7913delG13bp) are identified herein
for  the  first  time  in  African  population.  The  remaining
mutations (p.G61E, p.E173K, and g.4339delG) have been
previously reported in different populations [2].
It is noteworthy that four of these mutations (p.G61E,
p.E229K,  p.R368H,  and  g.7901–7913del13bp)  were
previously found in patients with POAG, Rieger’s syndrome
or Peters anomaly, and therefore are associated with different
glaucoma  phenotypes  [2].  Previous  structural  and/or
functional  studies  showed  that  the  previously  described
missense mutations alter at least one of the protein properties,
demonstrating their pathogenic character [25,45-47].
CYP1B1  is  a  member  of  the  cytochrome  P450
superfamily which shares a highly conserved COOH-terminal
core  (CCS)  involved  in  the  heme-binding  ability  of  the
structure. Human CYP1B1 is a 543 amino-acid long protein
which  is  made  up  of  three  regions:  the  53  residue-long
membrane-bound  NH2-terminal  region,  a  10  residue-long
proline rich region called “the hinge region,” and the 480
residue-long cytosolic globular domain which contains the
CCS  elements.  This  region  includes  four  helix-  bundles
(helices D, I, L, and the antiparallel helix E, helices J and K,
beta-sheets 1 and 2, the heme-binding region, and the meander
just NH2-terminal to the heme-binding region [48,49]. The
heme-binding region which harbors the invariant cysteine of
all known P450 proteins (i.e., Cys470 of CYP1B1) is essential
for the normal function of every P450 molecule [50]. All the
mutations reported herein, except p.G61E are located in the
cytosolic domain.
Novel  mutations—The  novel  mutations  we  reported
were  expected  to  be  pathogenic  based  on  the  following
criteria: the causing frame shift and creating of a stop codon
(g.4330–4331delTG), the nature of the amino-acid change it
TABLE 3. CYP1B1 SINGLE NUCLEOTIDE POLYMORPHISMS AND MUTATIONS DETECTED IN 20 PROBANDS WITH PRIMARY CONGENITAL GLAUCOMA.
Patient ID Mutation
g.3947C>G
(p.R48G)
g.4160G/T
(p.A119G)
g.8131C>G
(p.L432V)
g.8195A>G
(p.N453S)
PCG-3-III.3 g.4339delG/g.4339delG C/C G/G G/G A/A
PCG-4-IV.3 g.4339delG/g.4339delG C/C G/G G/G A/A
PCG-17-III.3 g.4339delG/g.4339delG C/G G/G G/G A/A
PCG-25-IV.3 g.4339delG/g.4339delG C/G G/G G/G A/A
PCG-1-II.5 p.E173K/g.4339delG C/G G/G G/G A/A
PCG-28-II.2 p.E173K/g.4339delG C/C G/G G/G A/A
PCG-64-III.1 g.4330–4431delTG/g.4339delG C/C G/G G/G A/A
PCG-84-V.2 g.4330–4431delTG/g.4330–
4431delTG
C/C G/G G/G A/A
PCG-95-III.2 g.4339delG/g.7901-7913del C/C G/G G/G A/A
PCG-11-II.1 g.4339delG/p.V364M C/C G/G G/G A/A
PCG-58-V.2 g.79017913del/g.7901-7913del C/C G/G G/G A/A
PCG-79-III.3 g.4339delG/p.G61E C/G G/G G/G A/A
PCG-47-II.3 p.G61E/p.G61E C/G G/G G/G A/A
PCG-89-V.3 p.G61E/p.G61E C/G G/G G/G A/A
PCG-97-II.3 p.G61E/p.G61E C/G G/G G/G A/A
PCG-14-II.2 p.R368H/w C/C G/G C/G A/G
PCG40-IV.6 p.R390S/p.R390S C/G T/T G/G A/A
PCG-75-IV.1 p.R469W/p. R469W C/C G/G C/C A/A
PCG-100-II.3 p.C470Y/p.C470Y C/G G/T C/C A/A
PCG-101-III.3 p.R163C/w G/G G/G C/G A/A
Only probands in whom a complete haplotype could be determined are included. w: normal allele.
Molecular Vision 2010; 16:1215-1226 <http://www.molvis.org/molvis/v16/a135> © 2010 Molecular Vision
1221caused, the degree of conservation, the absence of mutations
in controls, and Polyphen, PolypPhen-2, and SIFT prediction
(p.R163C and p.C470Y). These algorithms were recently used
to predict whether a missense mutation is likely to have or not
a deleterious effect [51-54].
The 4330–4331delTG mutation was found in two patients
carrying null alleles. It was homozygous in proband PCG-84-
V.2,  and  compound  heterozygous  (g.4339delG/g.4330–
4331delTG) in proband PCG-64-III.1. It was predicted to
truncate the CYP1B1 protein after the amino-acid 221 of F-
helix. The resulting protein therefore lacked a large part of the
important cytosolic domains. Because the COOH-terminal
half of the CYP1B1 protein is expected to be involved in
heme-binding and proper folding of the molecule [55], these
null allele eliminating the essential part of the P450 protein
obviously affect the structure and damage the function of
CYP1B1.
The  p.R163C  mutation  site  is  located  in  the  COOH-
terminal of the cytosolic loop connecting C- and D-helices. It
occurred  at  conserved  position  in  chimpanzee,  rhesus
monkey, cattle, mouse, rat, cat, and dog CYP1B1, although
not in zebrafish. Furthermore, a cysteine is never found in any
CYP1B1,  whatever  the  species  analyzed  at  this  position
(Figure  3).  The  p.R163C  was  not  found  in  200  control
chromosomes. Substitution of arginine to cysteine leads to a
change from a positively charged residue to a hydrophobic
and  uncharged  amino-acid.  This  may  affect  the  charge
distribution, and may destabilize ionic interactions, and thus
could  cause  a  conformational  change.  The  SIFT  score  of
p.R163C  was  0.01  and  is  predicted  to  affect  the  protein
function. The PolyPhen PSIC score of this mutation was 1.54
indicating  that  this  change  is  possibly  damaging.
Polyphen-2 program indicated that this mutation is probably
damaging. These data suggested that p.R163C is a pathogenic
mutation rather than a benign polymorphism.
The other novel mutation, p.C470Y, was homozygous in
patient PCG-100-II.3 from a consanguineous family. This
change substituted a hydrophobic residue to a hydrophilic
amino-acid.  At  this  position,  the  cysteine  is  absolutely
invariant (Figure 3) among the P450 family and is a part of
the  “signature  sequence”  (NH2-FXXGXXXCXG-COOH)
that is present in all heme binding cytochromes at the COOH-
terminus of the protein (serving as the axial ligand of the heme
iron). The cysteine in this sequence acts as the fifth ligand to
the heme [27]. This change is expected to interfere with the
ability  of  mutated  protein  to  perform  normal  physiologic
functions  and  probably  affects  severely  the  normal
metabolism  of  the  other  molecules  that  require  CYP1B1
participation. The SIFT score of p.C470Y was 0.00 and is
predicted to be deleterious for the protein function. The PSIC
score of this mutation was 4.173 indicating that this mutation
is probably damaging. PolyPhen-2 software confirmed this
result. These data strongly suggested that p.C470Y which
affect  a  critical  amino-acid  of  CYP1B1,  is  a  pathogenic
mutation.
Few reported studies showed that genotype/phenotype
correlation varies, depending on the type of mutation [56,
57]. Our data showed that the novel mutations are associated
with moderate (p.R163C) to severe (p.4330–4331delTG and
p.C470Y) phenotypes, based on the severity index proposed
by Panicker et al. [56]. This is not surprising since the patients
PCG-64-III.1 and PCG-84-V.2, carried deletions which are
suggested to create a null allele and p.C470Y affected a crucial
amino-acid of CYP1B1 and present at the homozygous state.
Most frequent mutations—In our study, g.4339delG
was  found  to  be  the  most  frequent  change,  followed  by
p.G61E.  These  two  mutations  together  were  present  in
37.21% (30.55 and 6.66%, respectively) of the Moroccan
studied  alleles.  The  g.4339delG  mutation  was  initially
described  in  Moroccan  patients  with  a  comparable  rate
Figure 3. Multiple amino-acid sequence alignment of CYP1B1 from different species. Sequence alignment was generated by ClustalW. The
positions of mutated amino-acids newly reported in this study are indicated by arrows and red letters. The COOH-terminal amino-acids of C-
helix, NH2-terminal amino-acids of D-helix and heme binding loop (HBL) are indicated below the sequence alignment, by a line.
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1222(25.80%  of  alleles)  [28].  It  is  also  the  most  frequent
CYP1B1 mutation among patients in Brazil [39] (21% of
chromosomes) with a lower percentage than in Moroccan
population.
This  relatively  high  frequency  of  g.4339delG,  in
Morocco, is likely due to a founder effect as it has been
previously suggested [28], as well as its ancient appearance
in Moroccan population [28]. In our study, g.4339delG was
found at the homozygous state in 24 of the 90 studied probands
(26.66%) and present in all of compound heterozygous. This
is  consistent  with  the  relatively  high  frequency  of
consanguinity (estimated at approximately 30%) and its rate
in Morocco. Although the p.E173K, p.V364M, and g.7901–
7913del13bp mutations have been previously described, their
association with g.4339delG is novel.
Rare mutations—All the remaining reported mutations
were infrequent in our PCG patient’s sample, each detected
in less than 2% (0.55%–1.66%) of the tested chromosomes.
Similarly to our study, the p.E173K, p.R390S, and g.7901–
7913del13bp mutations have been reported at a very low
frequency [2,34,35]. So far, a few PCG families were found
to have these mutations. However, p.R368H, p.V364M and
p.R469W have been reported to be among the most common
mutations in different populations [5,35,40,43,58,59].
CYP1B1 haplotype background: Most of the mutations
identified herein shared a common haplotype C/G/G/A (Table
3).  This  haplotype  has  been  previously  reported  in  PCG
patients  from  Saudi  Arabia,  Morocco,  Turkey,  and  India
indicating that founder effects must have occurred for most
CYP1B1  mutations  [5,28,60].  Particularly,  in  Moroccan
population,  a  founder  effect  has  been  suggested  for  g.
4339delG  [28].  Our  data  agree  with  the  founder  effect
hypothesis  for  p.G61E,  g.4339delG,  p.E173K,  g.4330–
4331delTG, and g.7901–7913del13bp. However, an extended
haplotype analysis is required to confirm this hypothesis.
Variable expression and incomplete penetrance of the
PCG phenotype: It is noteworthy that the p.R390S mutation
was associated with PCG and POAG, in a consanguineous
family  (PCG-40).  The  proband  (PCG-40-IV.6)  and  his
paternal  uncle  (PCG-40-III.1)  were  homozygous  for  this
mutation. The proband (PCG-40-IV.6) had a neonatal and
aggressive  form  of  PCG  with  severe  corneal  changes,
uncontrollable  IOP  higher  than  50  mmHg  leading  to  the
evisceration of the right eye at the age of 10 years. Despite
early and multiple surgical procedures, the visual outcome
was poor in this patient.
The residue R390 is located in the conserved alpha K-
helix and is a part of the consensus GluXXArg, which is
absolutely conserved among all members of the cytochrome
P450 family [48]. Structural data analysis suggested that the
p.R390S, along with p.R390H and p.R390C, could affect the
stability  of  the  CYP1B1  protein  [5,47].  Therefore,  this
homozygous mutation could explain the severe phenotype in
patient PCG-40-IV.6. Intriguingly, the uncle (PCG-40-III.1)
was diagnosed with POAG at the age of 45 years, showing the
association of p.R390S with different glaucoma phenotypes.
This suggests that additional factors are necessary for the
development of the glaucomatous process [26]. The molecular
association  between  PCG  and  JOAG  or  POAG  has  been
documented in few cases with CYP1B1 mutations [13,24,
25],  but  this  is  the  first  time  that  p.R390S  has  exhibited
variable expressivity of glaucoma.
It is interesting to note that p.E229K has been found in a
healthy  29-year-old  mother  (PCG-64-II.4)  who  carried  g.
4430–4431delTG  in  her  second  CYP1B1  allele.  She  was
recently re-examined and had no symptoms of glaucoma. This
mutation has been previously described in PCG patients and
also  in  healthy  carriers  [25,56,61].  The  association  of
p.E229K with a null allele raised the question of its potential
pathogenicity.  A  similar  situation  has  been  previously
reported  (p.E229K/c.1064–1076del)  [61].  Recently,
functional  studies  classified  the  p.E229K  variant  as  a
hypomorphic allele with decreased function, and suggested
that it could function as a risk allele, which can lead to the
development of glaucoma in the presence of modifiers or
environmental  influence.  It  has  also  been  proposed  that
reduced penetrance could be due to a dominant suppressor of
the  PCG  phenotype,  which  is  not  linked  genetically  to
CYP1B1, and/or the inducibility of CYP1B1 by environmental
lipophilic agents to which individuals may have been exposed
[45]. Therefore, the mother (PCG-64-II.4) is probably a case
of incomplete penetrance or delayed onset of glaucoma.
MYOC mutation associated with PCG: Previous studies
reported that mutations in MYOC or both of CYP1B1 and
MYOC have been detected in a small proportion of PCG cases
[7-9,20]. In our cohort, MYOC was involved in only one
patient (PCG-9-II.3) who was heterozygous for the p.T293K
mutation, suggesting a minor role of MYOC in the Moroccan
population.  This  mutation  has  been  initially  reported  in
patients with POAG or ocular hypertension [26,36-38], and
this is the first report of the association of p.T293K with PCG.
The proband PCG-9-II.3 carrying this mutation had advanced
glaucoma  at  presentation  and  intervened  belatedly.  The
outcome was bad in his case.
In our study three patients were heterozygous for only
one mutation in CYP1B1 or MYOC, and 46 (51.11%) didn’t
carry any mutation. These results suggest the possibility of
other candidate genes, or loci, not yet identified, that may be
involved  in  anterior  chamber  development  as  it  has  been
suggested by previous studies [10-12]. Given that only the
coding region of CYP1B1 and MYOC was sequenced, it is
possible that a promoter or another non-coding variant may
be present in heterozygous patients and among those who had
no mutations.
In summary, we identified three CYP1B1 novel mutations
in addition to the eight previously reported, and one MYOC
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1223mutation previously associated with POAG. Nearly 48% of
the patients carried CYP1B1 mutations; most of them (46%)
had two mutant alleles, with predominance of the g.4339delG
mutation. Thus, in Morocco, mutations of CYP1B1 are a major
cause for PCG, while MYOC gene plays a minor role. Our
results  will  be  useful  for  genetic  testing  and  genetic
counselling,  especially  for  the  g.4339delG  mutation  in
Moroccan patients. A better understanding of the genetics of
PCG will contribute to early diagnosis and prevention of this
severe blindness condition. Finally, despite the significant
role of CYP1B1 in Moroccan PCG, it is clearly evident that
other  genetic  and/or  environmental  factors  are  still  to  be
identified and that a concerted effort to identify the causative
genes would be useful.
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